GSK plc (NYSE:GSK) Shares Bought by Mission Wealth Management LP

Mission Wealth Management LP raised its holdings in GSK plc (NYSE:GSK) by 17.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,518 shares of the pharmaceutical company’s stock after purchasing an additional 1,555 shares during the period. Mission Wealth Management LP’s holdings in GSK were worth $356,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. FMR LLC grew its holdings in GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after purchasing an additional 2,224,345 shares during the period. Fisher Asset Management LLC grew its holdings in GSK by 1.4% in the fourth quarter. Fisher Asset Management LLC now owns 18,836,797 shares of the pharmaceutical company’s stock valued at $637,061,000 after purchasing an additional 259,867 shares during the period. Primecap Management Co. CA grew its holdings in GSK by 2.4% in the third quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock valued at $607,222,000 after purchasing an additional 342,365 shares during the period. Equity Investment Corp grew its holdings in GSK by 13.3% in the fourth quarter. Equity Investment Corp now owns 3,962,581 shares of the pharmaceutical company’s stock valued at $134,014,000 after purchasing an additional 466,327 shares during the period. Finally, Provident Trust Co. grew its holdings in GSK by 1.7% in the third quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock valued at $161,623,000 after purchasing an additional 66,765 shares during the period. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Stock Performance

Shares of GSK stock opened at $38.79 on Thursday. GSK plc has a one year low of $31.72 and a one year high of $45.92. The company has a market cap of $80.38 billion, a price-to-earnings ratio of 24.39, a PEG ratio of 1.12 and a beta of 0.58. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The business’s 50 day moving average price is $35.25 and its 200 day moving average price is $37.20.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. On average, research analysts predict that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a dividend of $0.3932 per share. This is an increase from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a yield of 4.05%. GSK’s dividend payout ratio (DPR) is presently 98.74%.

Analyst Ratings Changes

GSK has been the topic of a number of research analyst reports. Morgan Stanley initiated coverage on GSK in a research note on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and lowered their price target for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Seven research analysts have rated the stock with a hold rating and four have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.